Skip to main content
. 2016 Apr 26;7(21):30907–30923. doi: 10.18632/oncotarget.9023

Figure 9. Proposed mechanism of vemurafenib resistance.

Figure 9

In the presence of BRAF V600E inhibition (large red X), the BRAF/KRAS mutant cells, KTC1-VEM2, are able to drive activation of survival and proliferation pathways (PI3K/AKT and RAF/MEK/ERK) through the KRAS G12D mutation and increased RTK (EGFR and HER3) activation. The KRAS G12D mutation is insensitive to the actions of GTPase-activating proteins (small red X) and is constitutively active (orange asterisk).